Caregiver-specific outcomes in antidementia clinical drug trials: A systematic review and meta-analysis

Journal of the American Geriatrics Society

Volumn 53, Issue 6, 2005, Pages 983-990

  Lingler, Jennifer Hagerty ^a,b   Martire, Lynn M ^a   Schulz, Richard ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b FNP   (United States)

Author keywords

Caregivers; Cholinesterase inhibitors; Meta analysis

Indexed keywords

DONEPEZIL; NOOTROPIC AGENT; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; CAREGIVER; CLINICAL TRIAL; COMMUNITY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; META ANALYSIS; METHODOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; SYSTEMATIC REVIEW; WELLBEING; COST OF ILLNESS; DAILY LIFE ACTIVITY; OUTCOME ASSESSMENT; SOCIOECONOMICS; STATISTICS; TIME;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; CAREGIVERS; CHOLINESTERASE INHIBITORS; COST OF ILLNESS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 23444451095     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.53313.x     Document Type: Review

References (48)

1. Jorm AF, Jolley D. The incidence of dementia: A meta-analysis. Neurology 1998;51:728-733.
2. Ernst RL, Hay JW. Economic research on Alzheimer's disease: A review of the literature. Alzheimer Dis Assoc Disord 1997;11(Suppl 6):135-145.
3. Doody RS, Stevens JC, Beck C et al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Committee of the American Academy of Neurology. Neurology 2001;56:1154-1166.
4. Cummings JL, Frank JC, Cherry D et al. Guidelines for managing Alzheimer's disease, part II. Treatment. Am Fam Physician 2002;65:2525-2534.
5. Ritchie CW, Ames D, Clayton T et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease. Am J Geriatr Psychiatry 2004;12:358-369.
6. Trinh N, Hoblyn J, Mohanty S et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. JAMA 2003;289:210-216.
7. Cummings JL. Use of cholinesterase inhibitors in clinical practice: Evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131-145.
8. Rogers SL, Farlow MR, Doody RS et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
9. Winblad BB, Brodaty H, Gauthier S et al. Pharmacotherapy of Alzheimer's disease Is there a need to redefine treatment success? Int J Geriatr Psychiatry. 2001;16:653-666.
10. Wimo A, Winblad B, Engedal K et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: Results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003;15:44-54.
11. Wimo A, Winblad B, Stoffler A et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003;21:327-340.
12. Acton GJ, Kang J. Interventions to reduce the burden of caregiving for an adult with dementia: A meta-analysis. Res Nurs Health 2001;24:349-360.
13. Sorensen S, Pinquart M, Duberstein P. How effective are interventions with caregivers: An updated meta-analysis. Gerontologist 2002;42:356-372.
14. Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc 2003;51:657-664.
15. Martire LM, Lustig A, Schulz R et al. Is it beneficial to involve a family member? A meta-analysis of psychosocial interventions for chronic illness. Health Psychol 2004;23:599-611.
16. Diagnostic and Statistical Manual of Mental Health Disorders, 4th Ed. Washington, DC: American Psychiatric Association, 1996.
17. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
18. Verhagen AP, de Vet HCW, de Bie RA et al. The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998;51:1235-1241.
19. Rosenthal R. Meta-Analytic Procedures for Social Research. Newbury Park, CA: Sage Publications, 1991.
20. Shikiar R, Shakespeare A, Sagnier P et al. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: Results from the MALT clinical trial. J Am Geriatr Soc 2000;48:268-274.
21. Courtney C, Farrell D, Gray R et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD 2000): Randomized double-blind trial. Lancet 2004;363:2105-2115.
22. Borenstein M, Rothstein H. Comprehensive Meta-Analysis: A Computer Program for Research Synthesis. Englewood, NJ: Biostat Inc., 1999.
23. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd Ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
24. Jones RW, Soininen H, Hager K et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:58-67.
25. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Move Disord 2001;16:1171-1174.
26. Wilkinson DG, Passmore AP, Bullock R et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002;56:441-446.
27. Wilcock G, Howe I, Coles H et al. A comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003;20:777-789.
28. Moretti R, Torre P, Antonello RM et al. Rivastigmine in subcortical vascular dementia: An open 22-month study. J Neurol Sci 2002;203-204:141-146.
29. Kaufer DI, Catt K, Pollock B et al. Assessing the effects of donepezil in Alzheimer's patients and its impact on caregiver. J Am Geriatr Soc 1998;46:S66.
30. Matthews HP, Korbey J, Wilkinson DG et al. Donepezil in Alzheimer's disease: Eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 2000;15:713-720.
31. Patterson CE, Passmore AP, Crawford VL. A 6-month open-label study of the effectiveness and tolerability of galantamine in Alzheimer's disease. Int J Clin Pract 2004;58:144-148.
32. Clipp EC, Moore MJ. Caregiver time use. An outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther 1995;58:228-236.
33. Cummings JL, Schneider L, Tariot PN et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Geriatr Psychiatry 2004;161:532-538.
34. Feldman H, Gauthier S, Hecker J et al. Effect of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and effect on caregiver burden. J Am Geriatr Soc 2003;51:737-744.
35. Robert PH, Lebert F, Goni S et al. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. 152nd Annual Meeting of the American Psychiatric Association, Washington, DC: May 15-20, 1999.
36. Sano M, Wilcock GK, van Baelen B et al. The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry 2003;18:942-950.
37. Kaufer DI, Cummings JL, Christine D et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998;46:210-215.
38. Vitaliano PP, Russo J, Young HM. The Screen for Caregiver Burden. Gerontologist 1991;31:76-83.
39. Pearlin LI, Mullan JT, Semple SJ et al. Caregiving and the stress process: An overview of concepts and their measures. Gerontologist 1990;30:583-594.
40. Greene JG, Smith R, Timbury GC. Measuring behavioral disturbances of elderly demented patients in the community and its effects on relatives: A factor analytic study. Age Ageing 1982;11:121-126.
41. Poulshock SW, Deimlmg GT. Families caring for elders in residence. Issues in the measurement of burden. J Gerontol 1984;39:230-239.
42. Blesa R. Galantamine: Therapeutic effects beyond cognition. Dement Geriatr Cogn Disord 2000;11(Suppl 1):28-34.
43. Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
44. Mohs RC, Doody RS, Morris JL et al. A 1-year placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-488.
45. Wimo A, Wetterholm AL et al. Evaluation of the resource utilization and caregiver time in anti-dementia drug trials: A quantitative battery. In: Wimo A, Jönsson B, Karlsson G, eds. The Health Economics of Dementia. London: John Wiley & Sons, 1988, pp 465-499.
46. Moher D, Schulz K, Altman D et al. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-1991.
47. Des Jarlais DC, Lyles C, Crepaz N et al. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND Statement. Am J Public Health 2004;94:361-366.
48. Hedges LV, Vevea JL. Fixed- and random-effects models in meta-analysis. Psychol Meth 1998;3:486-504.